Your search returned 3 results.

Results
	1.	Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing. [electronic resource] by Faber, Edgar Nausová, Jitka Jarosová, Marie Egorin, Merrill J Holzerová, Milena Rozmanová, Sárka Maresová, Ivana Divoký, Vladimír Indrák, Karel Producer: 20070925 In: Leukemia & lymphoma vol. 47 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment. [electronic resource] by Faber, Edgar Divoká, Martina Skoumalová, Ivana Novák, Martin Marešová, Ivana Mičová, Kateřina Friedecký, David Adam, Tomáš Jarošová, Marie Indrák, Karel Publication details: Leukemia & lymphoma Feb 2016 In: Leukemia & lymphoma vol. 57 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial. [electronic resource] by Faber, Edgar Pytlík, Robert Slabý, Jirí Zapletalová, Jana Kozák, Tomás Raida, Ludek Papajík, Tomás Zikesová, Eva Maresová, Ivana Hamouzová, Marie Indrák, Karel Trnený, Marek Producer: 20070103 In: European journal of haematology vol. 77 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)